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infliximab [IFX]). Treatment efficacy was measured using ACR-responses (ACR20,
ACR50 or ACR70) at 6 months. ACR estimated response rates were based on ad-
justed indirect comparison (MTX as the common comparator) of published clinical
trials. Utilities were derived from EQ-5D data collected in CZP RA clinical trials.
Clinical history and resource use data came from published literature. Unit costs
(drug, administration, monitoring, and resources) were taken from Spanish routine
sources or published references (cost year 2009). Base case analysis was conducted
from the payer perspective, with a lifetime horizon, annual discounting rates of
costs and outcomes of 3.5% and inflation rate for 2009 onwards of 3%. One-way
sensitivity analyses were conducted. RESULTS: The average lifetime costs for
CZPMTX, ETAMTX, ADAMTX and IFXMTX were €140,971, €141,197, €139,148
and €136,961, respectively. The quality-adjusted life-years (QALYs) gained were
6.578, 6.462, 6.430 and 6.318, respectively. The deterministic cost-effectiveness
analysis found that CZPMTX dominated ETAMTX (lower cost, greater QALYs),
and that CZPMTX was cost-effective vs ADAMTX and IFXMTX at the €30,000/
QALY willingness-to-pay threshold (ICERs of €12,346/QALY and €15,414/QALY, re-
spectively). One-way sensitivity analyses showed that ICERs were most sensitive to
the change in annual discount rates, the model cycle (evaluation of ACR response
at 3 instead of 6 months), the analysis perspective and the estimation of utilities
(HAQ-DI mapping instead of direct evaluation from EQ-5D). CONCLUSIONS: This
analysis shows that CZPMTX is cost-effective versus the other considered TNF-
inhibitors recommended in Spain for the treatment of RA.
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OBJECTIVES: To evaluate the cost-effectiveness of golimumab (Gol) treatment in
severe, active Ankylosing Spondylitis (AS). METHODS: A Markov model was con-
structed based upon the literature, to model the progression of a cohort of AS
patients treated with Gol and its comparators over a 20 year time frame. The
comparators considered were adalimumab (Ada) and etanercept (Eta) and all were
compared to standard care which was comprised of a combination of nonsteroidal
anti-inflammatory drugs (NSAIDs), disease modifying antirheumatic drugs
(DMARDs), Cox-2 inhibitors and physiotherapy. Long-term efficacy was based on
regressions estimated from the Gol phase III trial (GO RAISE) and the literature.
Short-term comparative efficacy was derived from a mixed treatment comparison.
The outcome measure was quality-adjusted life-years (QALYs). Utilities were esti-
mated through use of an algorithm translating BASFI and BASDAI progression to
EQ-5D. Costs were based on the literature (long-term) and expert opinion (short-
term). Uncertainty was explored through deterministic and probabilistic sensitiv-
ity analysis (PSA). RESULTS: Compared to conventional therapy, the incremental
cost-effectiveness ratios (ICERs) of the biologic TNF- inhibitors Gol, Ada and Eta
were £30,043, £30,187 and £30,810 respectively, with the TNF- inhibitors having
similar QALYs and costs. In the sensitivity analysis, time horizon and baseline
BASFI and BASDAI scores had the biggest impact on the results. Gol was seen to
provide the greatest net monetary benefit (NMB) of all the TNF- inhibitors at all
willingness to pay (WTP) thresholds up to £30,000 per QALY. CONCLUSIONS: Gol is
a highly effective and well-tolerated therapy for the treatment of patients with
severe, active AS and represents a treatment option with similar cost-effectiveness
versus conventional care as the TNF- inhibitors currently approved by the Na-
tional Institute for Health and Clinical Excellence (NICE) in the UK.
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OBJECTIVES: To estimate the cost-utility of denosumab compared with generic
alendronate, generic risedronate, oral ibandronate, strontium ranelate and no
treatment to prevent osteoporotic fractures in Spanish postmenopausal women.
METHODS: A validated Markov cohort model was adapted to the Spanish osteopo-
rotic patient population (women aged 65 years, T-score2.5 SD and a prevalence
of morphometric vertebral fractures of 36%) to represent the possibility of transi-
tioning through different health states: well, hip fracture, vertebral fracture, wrist
fracture, other osteoporotic fractures, post-vertebral fracture, post hip fracture and
death. Efficacy data on fracture risk reduction were derived from a phase III trial for
denosumab versus placebo and a meta-analysis conducted by NICE for compara-
tors with follow-up of one to three years. The perspective of the Spanish National
Healthcare System was used and costs were referred to 2010. The model included
treatment persistence during the intended 5-year treatment period and assumed a
two year linear decline in efficacy after discontinuation. Persistence data for all
treatments were obtained from prescription data and a persistence study. Results
were presented in incremental cost-effectiveness ratios (ICERs). RESULTS: The
base-case ICERs were estimated at €17,345, €25,397, and €14,543 per QALY for de-
nosumab compared with no treatment, generic alendronate, and generic risedro-
nate. Denosumab was dominant against oral ibandronate and strontium ranelate
since resulted in lower costs and better efficacy. CONCLUSIONS: This analysis
showed that denosumab is a cost-effective treatment option compared to oral
osteoporosis treatments.
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OBJECTIVES: Rituximab (MabThera™) selectively targets B cells and represents an
effective therapeutic approach for RA in addition to existing treatments, such as
disease-modifying anti-rheumatic drugs (DMARDs) and tumour necrosis factor
(TNF) inhibitors. This study explores the cost-effectiveness of rituximab in TNF-IR
patients in the The Netherlands. METHODS: The analysis reflects efficacy of the
compared strategies based on two parameters: ACR response and HAQ score. A
network meta-analysis provided evidence on the comparative efficacy of treat-
ments based on ACR response. Evidence from the REFLEX trial and secondary
sources are used to project HAQ score changes of patients over time. Cost input for
the analysis is derived from local sources in the The Netherlands. Utility data
(EQ-5D) from a patient registry is analysed and categorised into six HAQ score
bands based on disease severity. All input is synthesised through an individual
simulation model that compares three treatment strategies after failure of a first
TNF: one sequence containing rituximab, one containing TNF (i.e. TNF-cycling) and
one containing abatecept. Uncertainty around model parameters is explored
through probabilistic sensitivity analysis. A scenario analysis uses data on loss of
productivity to estimate the indirect costs of the comparing strategies.RESULTS: In
the base-case analysis, the strategy with rituximab dominates the other strategies.
The result is the same in probabilistic sensitivity analysis where over 98% of the
samples show that the sequence with rituximab dominates both other strategies.
CONCLUSIONS:The addition of rituximabMTX in the standard of care of patients
with inadequate response to TNF treatment is estimated to be a cost-effective
strategy.
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OBJECTIVES: We developed a cost-effectiveness model of biological therapy (BT)
compared with methotrexate (MTX) alone, using a combination of information
from 150 patients at Hospital Militar in Bogota, Colombia, and from international
trials and economic aggregated data. METHODS: We designed a Markov model
with five functional states, based on Health Assessment Questionnaire (HAQ). Five
simulations were estimated through hypothetical cohorts of patients, with similar
characteristics to our observed sample, who initiated treatment in each of the five
states defined for the disease. Simulations were run for 10 and 20 years under
different scenarios. Utilities, in QALY were taken from Tufts CEA Registry. Discount
rates: 6% for costs and 1.5% for utilities. We calculated both direct and indirect
costs, converted into US dollars. RESULTS: In the ten-year base case, incremental
cost effectiveness ratios (ICER) (in US$ per additional QALY gained) for each of the
five functional states in increasing severity order, were $153,184; $139,466;
$130,281; $134,752 and $109,934,respectively. In the twenty-year base case, ICERs
were $119,025; $112,921; $108,124; $110,520 and $98,119, respectively. Total costs
were lower with MTX, despite higher indirect costs and complication costs. How-
ever, BT treatment represented more QALYs regardless of the initial state. More-
over, it is more cost-effective to start the treatment from advanced disease states.
BT would not be cost-effective in Colombia when using WHO cost-effectiveness
threshold (3 times per capita GDP of US$6200) and even less so using other thresh-
olds (US$ 50,000; €50,000 or £30,000 per QALY gained). CONCLUSIONS: BT com-
pared to MTX provides more QALYs to the patients, but at a high cost. When ICERs
were estimated for Colombia, BT would not be cost effective under usual thresh-
olds. A serious dilemma arises. We suggest establishing different thresholds for
different conditions, giving priority to chronic diseases that can lead to serious
disability.
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OBJECTIVES: There are 5 anti-TNF agents licensed for the treatment of RA in Ire-
land; adalimumab, certolizumab pegol, etanercept, golimumab and infliximab. Re-
imbursement agencies have issued mixed approvals for their use through either a
multiple assessment process or a single technology appraisal process. Significant
uncertainties have been identified through these assessments. A multiple treat-
ment comparison of these agents, focusing on the uncertainties previously high-
lighted, in the Irish health care setting is the focus of this study. METHODS: The
Birmingham Rheumatoid Arthritis Model 2009 was used to estimate the cost effec-
tiveness of anti-TNF agents in patients with established RA who were non-re-
sponders to methotrexate. The perspective taken is that of the Irish Healthcare
Payer. Evidence synthesis of HAQ data (via a multiplier), long and short term sur-
vival data was performed in WinBUGs and used to inform the effect parameter in
the model. Irish cost data was applied. Utility mapping between HAQ, EQ-5D (re-
vised scoring) and SF-6D was used to model utility gain. Probabilistic analysis was
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performed. RESULTS: Incremental cost effectiveness ratios were calculated for
each anti-TNF in comparison to methotrexate. Infliximab is dominated in almost
all scenarios, being more costly and less effective. Etanercept and adalimumab are
the most effective options and most costly. Golimumab appears less effective and
less costly. Sensitivity analysis around utility measure and HAQ improvement as-
sumptions indicate that these are key drivers to the estimates. CONCLUSIONS:
This CUA focuses on novel methods for data inputs estimation. Both Bayesian and
frequentist methods are employed in order to validate the sub models used. The
outputs from the cost utility model show that etanercept and adalimumab appear
most effective on the cost effectiveness plane. However they are also more costly
than both golimumab and certolizumab pegol.
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OBJECTIVES: Falls/Slips cases injured with over the level two and their medical
costs for a year of 2008 at 3 teaching hospitals are explored. METHODS: There are
2559, 1394, and 4086 incident reports in 2008 collected at St. Mary’s Hospital, Shi-
mane University Hospital, and Kyoto University Hospital, Japan. Their reports in-
clude 565, 399, and 561 cases for Falls/Slips. The cases are classified 264, 176, and
306 cases with level 2, and 89, 32, and 82 cases with level 3a, and 8, 3, and 5 cases
with level 3b, respectively. We explored 963 cases with over level 2 in order to
calculate additional medical costs by using their own administrative profiling data.
RESULTS: According to the injury level, average AMCs are 108 at SMH, 175 at SUH
and, 72 USD at KUH (level 2), respectively. Similarly, Average AMCs are 122, 223, and
97 USD (level 3a), and 1,431, 7,745 and 33,357 USD (level 3b), respectively.With
regard to clinical services, AMC with diagnostic imaging is the highest (10,118 USD,
SMH; 14,090 USD, SUH), but AMC with surgery/treatment is the highest at KUH,
92,115 USD. AMC with surgery/treatment is 6900 USD at SMH, and 8879 USD at SUH,
AMC with iv/div is 1275 USD at SMH and 1818 USD at SUH, AMC with laboratory
examination is 674 USD at SMH, and 899 USD at SUH, and AMC with drug admin-
istration is 455 USD at SMH and 318 USD at SUH. By contrast, AMCs at KUH are
11578 USD (imaging), 11290 USD (examination), 3372 USD (drug administration),
and 714 USD (iv/div), because AMC with level 3b and over is the highest by clinical
services. CONCLUSIONS: Therefore, Hospital administrators and policy makers
have to take appropriate measures to prevent patients from Falls/Slips and save
money, because this amount is not overlooked.
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OBJECTIVES: To assess the impact of ankylosing spondylitis (AS) on work produc-
tivity, to determine factors influencing work productivity and to estimate produc-
tivity costs incurred by AS in the Czech Republic. METHODS: A questionnaire in-
cluding Work Productivity and Activity Impairment Questionnaire (WPAI:AS),
Health Assessment Questionnaire (HAQ) and Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI) were filled out by 230 patients with AS in productive age.
The interdependence between HAQ, BASDAI, disease duration, age and WPAI:AS
scores were described by Spearman=s rank correlation coefficient. We have ana-
lyzed differences between work-active and all patients (work-active  disable)
groups, effect of biological treatment and education level on work productivity.
Productivity costs were calculated by friction cost approach (FCA) using friction
period of 130 work-days and average monthly gross income as denominator.
RESULTS: Average patients= age was 49.3 years (22-61) and average disease dura-
tion 18.0 years. Mean HAQ and BASDAI were 0.99 and 4.43, respectively. We re-
ported significantly greater loss in work productivity (p-value0,001) and daily
activities impairment (p-value0,001) for disable patients in compare to work-
active patients, differences were by 35.6% and 19.6%, respectively. AS in work-
active patients group was associated with 40.7% reduction in work productivity and
40.3% reduction in daily activities. Work-active patients group revealed signifi-
cantly lower age (p-value0,001), lower BASDAI (p-value0,001) and lower HAQ
(p-value0,001). Work absenteeism was weakly correlated with BASDAI and HAQ.
Work presenteeism and overall work impairment were moderately correlated with
BASDAI and HAQ, whereas impairment of daily activities was strongly correlated
with all four WPAI domains. Average annual productivity costs per one patient
were €2923 in all patients group. CONCLUSIONS: HAQ, BASDAI and age signifi-
cantly influence patients’ productivity. Patients on biologics had lower impairment
of daily activities and work productivity and revealed lower HAQ and BASDAI as
well. Average annual productivity costs per one patient were €2923.
Muscular-Skeletal Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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OBJECTIVES: The economic impact of therapeutic non-adherence has been rarely
examined in chronic diseases. This study aims to estimate the impact of non-
adherence with osteoporosis medications on clinical and economic outcomes and
to evaluate the economic value of improving patient compliance using hypotheti-
cal interventions. METHODS: A previously validated Markov microsimulation
model was adapted to the Irish setting to estimate long-term costs and outcomes
(fractures, life years and quality-adjusted life-year (QALY)) for three adherence
scenarios: no treatment, real-world adherence and full adherence over 3 years. The
real-world adherence employed compliance and persistence data from the Irish
HSE-PCRS pharmacy claims database. The number of fractures associated with
poor adherence and the incremental cost per QALY gained between the adherence
scenarios was estimated. We also investigated the cost-effectiveness of hypothet-
ical adherence-enhancing interventions according to their cost and effect on ad-
herence (improvements between 10% and 50%). RESULTS: The number of fractures
prevented and the QALY gain obtained at real-world adherence levels represented
only 57% and 56% of those expected with full adherence, respectively. Over 3 years,
a total number of 3,340 fractures including 1,271 at the hip were estimated to be
associated with non-adherence, resulting in a loss of 3,044 QALYs. The costs per
QALY gained of real-world adherence and of full adherence compared with no
treatment were estimated at €11,834 and €6,341. An intervention to improve ad-
herence by 25% would result in an ICER of €11,392/QALY and €54,182/QALY if the
intervention cost an additional €50 and €100 per year, respectively. CONCLUSIONS:
Poor adherence with osteoporosis medications results in a 50% reduction in the
potential benefits observed in clinical trials and a doubling of the cost per QALY
gained from these medications. Depending on their costs and outcomes, adher-
ence-enhancing interventions have the potential to be an attractive approach to
improve the allocation of resources.
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OBJECTIVES: The present study investigates the treatment persistence of osteopo-
rosis and assesses its impacts on the risk of fractures among women in Taiwan.
METHODS: This is a retrospective cohort study design. Patients who filled prescrip-
tions of alendronate, ibandrobate, risedronate, zoledronate, raloxifene or teripa-
ratide during 2005-2009 were retrieved from the National Health Insurance Re-
search database. Non-persistence was defined when the patients did not refill
prescription within 30 days after the previous osteoporosis prescriptions. Relative
risks of fracture incidence within 3 years after the initial prescription date in four
persistence groups (30 days, 1 month-1 year, 1-2 years, 2-3 years) were evaluated
based upon survival analysis. RESULTS: A total of 1,287,253 patients were included
and followed during the study period of 2005-2009. The overall persistence rates
among patients with osteoporosis drug treatment were 37%, 29%, 21%, and 9% after
1, 2, 3, and 4 years, respectively. Risks of fractures were higher in the lower persis-
tence group (HR 0.87, p0.092 in 1 month-1 year persistence; HR 0.61, p0.001 in 2-3
years persistence). CONCLUSIONS: The relatively high non-persistence rates
among patients with osteoporosis treatment and the significant negative associa-
tion between treatment persistence and fracture incidence indicates potential
cost-savings and health gains are substantial if improvement in the treatment
persistence can be achieved.
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OBJECTIVES: To study self-estimates of rheumatoid arthritis (RA) patients regard-
ing their future health related quality of life and to assess the acceptability of
different health problems at certain stages of life. METHODS: A cross-sectional
survey was performed in 12 rheumatology centres. RA patients initiating first bio-
logical therapy were involved. Disease activity (DAS28) was registered, health sta-
tus (EQ-5D) and functional disability (HAQ-DI) questionnaires were applied. Partic-
ipants were asked to indicate the health status they expect in 3 months time and
for ages 60, 70 and 80 years, using the health problem descriptions of the EQ-5D.
Concerns regarding ”some” and ”severe problems” in the dimensions of the EQ-5D
and HAQ-DI were surveyed by age (acceptable from age 30, 40, 50, 60, 70, 80 or
never). RESULTS: Altogether 116 patients (87.4% females) were involved, mean
(SD): age 52.3 (11.7) years, disease duration 9.3 (8.3) years, DAS28 6.17 (0.89), EQ-5D
score 0.348 (0.358), HAQ-DI 1.476 (0.653). Expected status after 3 months: EQ-5D
0.759 (0.270), HAQ-DI 0.648 (0.593). Patient expect to have significantly worse EQ-5D
scores at ages 60, 70 and 80 than the actual age specific general population has,
mean (SD): 0.438 (0.373) versus 0.728 (0.012); 0.240 (0.406) versus 0.682 (0.016) and
0.070 (0.411) versus 0.615 (0.024), respectively. The majority (26.3%-39.5%) pointed
that ”some problems” in five dimensions of the EQ-5D are acceptable from age 70.
The ”severe problems” level was rejected as never acceptable (54.3%-68.0%) except
the ”usual activities” dimension wherat extreme problems were accepted from age
80 by 47.1%. Similar outcomes were found with the HAQ-DI. CONCLUSIONS: RA
patients initiating biological drug expect quick improvement but prognosticate
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